NCT04317430

Niclosamide Role in Diabetic Nephropathy

Possible Role of Niclosamide in Patients With Diabetic Kidney Disease: Randomized Controlled Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is randomized, controlled, parallel, prospective clinical study will be conducted on 60 patients diagnosed with type 2 diabetes mellitus at least five years ago. Patients will be recruited from Tanta University Hospital, Tanta, Egypt. Accepted patients will be randomized into 2 groups as the following: Control group: 30 patients will receive maximum tolerated dose of ACEI plus placebo pills for six months Treatment group: 30 patients will receive maximum tolerated dose of ACEI plus niclosamide tablets 1 gram once daily for six months The primary end point will be the change in Urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) after six months of treatment

Conditions

• Diabetic Nephropathies

Interventions

Type	Name	Description
DRUG	Niclosamide	Niclosamide tablets 1 gram once daily
DRUG	Placebo oral tablet	lactose tablets

Timeline

• Start date: 2020-02-01
• Primary completion: 2022-04-01
• Completion: 2022-04-01
• First posted: 2020-03-23
• Last updated: 2022-10-20

Locations

1 site across 1 country: Egypt